The program described in this grant application will train post-doctoral fellows for an academic career in hematopoietic cell transplantation. Candidates with either an M.D. or M.D./Ph.D. degree who have completed training in internal medicine and either hematology or oncology will be considered for the one to two year training program. Prior to the training program, all individuals spend one year in a clinical fellowship in hematopoietic cell transplantation. During this clinical phase, trainees are exposed to the full spectrum of hematopoietic cell transplantation including autologous and allergenic transplantation from related and unrelated donors. The trainees'experience is centered in the Blood and Marrow Transplantation (BMT) inpatient unit at Stanford University Hospital and exposure to outpatient care is provided in the Cancer Center and Clinics. The trainees also conduct one month rotations through the Cellular Therapeutics and Transplantation and HLA laboratories. Following completion of the clinical rotations, trainees will spend approximately one to two years of in-depth study with a member of the faculty. These faculty members are individuals whose research focuses on the basic science and clinical application of hematopoietic cell transplantation. Intensive laboratory experience will prepare the trainee for a career in academic hematopoietic cell transplantation. In addition, the trainees will be responsible for the conduct of a clinical trial which is either on-going or developed in consultation with a member of the BMT Division faculty. At the conclusion of training, individuals will be prepared for a career as independent investigators well-studied in the basic and clinical areas of hematopoietic cell transplantation.
The Division investigates the biology of hematopoietic cell transplantation and the translation of concepts to the clinic to improve the outcomes of patients with cancer. One of the aims of the training program is to ensure that individuals get exposure to all of the facets of our program such that they will become leaders in the field and continue to explore novel strategies to cure cancer.
|Msaouel, Pavlos; Lam, Anthony P; Gundabolu, Krishna et al. (2014) Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity. Haematologica 99:930-6|
|Dunleavy, Kieron; Pittaluga, Stefania; Maeda, Lauren S et al. (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368:1408-16|
|Lam, Anthony P; Gundabolu, Krishna; Sridharan, Ashwin et al. (2013) Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia. Am J Hematol 88:E245-9|
|Meyer, Everett H; Hsu, Andro R; Liliental, Joanna et al. (2013) A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease. Blood 121:4955-62|
|Gill, Saar; Vasey, Adrianne E; De Souza, Alysha et al. (2012) Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood 119:5758-68|
|Logan, Aaron C; Weissman, Irving L; Shizuru, Judith A (2012) The road to purified hematopoietic stem cell transplants is paved with antibodies. Curr Opin Immunol 24:640-8|
|Warsch, Sean; Hosein, Peter J; Maeda, Lauren S et al. (2012) A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. Leuk Lymphoma 53:1299-1305|
|Herges, Katja; de Jong, Brigit A; Kolkowitz, Ilan et al. (2012) Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler 18:398-408|
|Maeda, Lauren S; Lee, Mark; Advani, Ranjana H (2011) Current concepts and controversies in the management of early stage Hodgkin lymphoma. Leuk Lymphoma 52:962-71|
|Chen, George L; Arai, Sally; Flowers, Mary E D et al. (2011) A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood 118:4070-8|
Showing the most recent 10 out of 17 publications